CA-AERA-TECHNOLOGY
Aera Technology today announced the general availability of the Aera Cognitive Operating System™, the world's first cloud platform for Cognitive Automation . In extending availability beyond current customers and partners, including Merck, RB, and Unilever, Aera meets the growing need of companies whose operations have been impacted by changing or uncertain market conditions.
“We’ve worked with the world's largest organizations and complex supply chains to demonstrate the value of Cognitive Automation at scale. This tight collaboration has enabled us to build the Aera Cognitive Operating System™, which is now easy to implement and scale, and therefore available to an even wider range of companies,” said Frederic Laluyaux, CEO of Aera Technology.
Alessandro de Luca, CIO of Healthcare, Merck Group, noted, “We are all running on much shorter cycles in this dynamic world, and it is impossible to process everything manually or on legacy systems. Aera's Cognitive Operating System™ has made a real difference in our ability to implement and operate a best-in-Class IBP process. This, combined with the fact that we could rely on a single, intelligent source of truth, gave us a springboard to agility.”
“Cognitive Automation plays a large role in the 4th industrial revolution,” said Nokuthula Lukhele, Project Lead, Data, and Digital Transformation, World Economic Forum. “The future of agility needs to be at the edge of decision making, and these technologies enable that,” she added.
The Aera Cognitive Operating System™ augments and enhances human decisions, providing a centralized corporate brain - adding agility to enterprise systems. By applying data crawling, machine learning, and industry models, Aera’s system makes real-time recommendations, predicts outcomes, and acts autonomously to aid complex decisions - from inventory optimization and touchless planning to order management and trade promotions.
“There is a limit of what the human mind can do with the volume of data and analytics needed to optimize a supply chain,” said Bish Sen, Head of Supply Chain Beauty & Personal Care, Transformation, Planning & Engineering at Unilever. “This is where agility is more important than accuracy, and Cognitive Automation can help unlock those levels of agility.”
“Designing and managing a supply chain that balances customer service, cost, and resiliency requires a model that constantly measures and reacts to value at risk. Kearney’s Sense & Pivot approach, combined with Aera’s Cognitive Operating System™, provides a proven solution agile enough to respond to this challenge by delivering real-time Cognitive Automation at scale for corporate boards and supply chain leaders.” - Suketu Gandhi, Partner, Global Leader - Digital Supply Chain, Kearney.
Aera Technology is hosting the Cognitive Automation Summit on September 24, 2020. This first summit dedicated to Cognitive Automation offers a unique opportunity to understand how the tectonic shift in cloud-scale and in artificial intelligence, along with radical market volatility are forcing enterprises to redefine agility. Thought leaders and pioneers from world-leading organizations will share how they leverage Aera’s Cognitive Operating System™ to achieve previously unattainable levels of financial and operational performance - without trade-offs.
For more information, visit https://cognitiveautomationsummit.com/ .
Aera also announced this week the launch of Aera Developer™, a self-service integrated development environment, which has been purpose-built for implementing Cognitive Automation at scale. It integrates each component of Data, Science, Process, and Change, so that it has all of the capabilities necessary for building Cognitive Skills, all rolled into one seamless user experience.
About Aera Technology
Aera Technology delivers the Cognitive Operating System™ that enables the Self-Driving Enterprise™. Aera understands how businesses work; makes real-time recommendations; predicts outcomes; and acts autonomously. Using proprietary data crawling, industry models, machine learning and artificial intelligence, Aera is revolutionizing how people relate to data and how organizations function. Headquartered in Mountain View, California, Aera services some of the world's largest enterprises from its global offices located in San Francisco, Bucharest, Cluj-Napoca, Paris, Munich, London, Pune, and Sydney. For more information about Aera, please visit www.aeratechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom